Sugi Predict
/ Targets
/ CCNT2
Top predicted compounds (top 20 by supporting neighbours, then confidence)
Clinical trials — most relevant to CCNT2 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt |
PHASE4 | COMPLETED |
| Adherence and Safety of Ribociclib Plus Aromatase Inhibitors in Patients With Early Stage, HR+ and HER2- Breast Cancer |
PHASE4 | NOT_YET_RECRUITING |
| Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas |
PHASE2 | RECRUITING |
| Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer |
PHASE2 | RECRUITING |
| Cyclin D1 Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at Clinical N2 Stage |
PHASE2 | RECRUITING |
| Abemaciclib + Pembrolizumab In Glioblastoma |
PHASE2 | WITHDRAWN |
| Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression |
PHASE2 | COMPLETED |
| Histology-Independent Study of Palbociclib in Patients With Advanced Cancer |
PHASE2 | WITHDRAWN |
| CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer |
PHASE2 | ACTIVE_NOT_RECRUITING |
| A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors |
PHASE1/PHASE2 | RECRUITING |
| G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer |
PHASE1/PHASE2 | UNKNOWN |
| Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) |
PHASE1/PHASE2 | RECRUITING |
| Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6 |
PHASE2 | RECRUITING |
| Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor. |
PHASE1/PHASE2 | COMPLETED |
| Abemaciclib With or Without Atezolizumab for mCRPC |
PHASE2 | COMPLETED |
| A Phase II Clinical Trial to Study the Efficacy and Safety of a New Drug P276-00 in Treatment of Recurrent and/or Locally Advanced Head and Neck Cancer |
PHASE2 | COMPLETED |
| Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer |
PHASE2 | COMPLETED |
| A Study of Abemaciclib in Recurrent Glioblastoma |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Bortezomib in Treating Patients With Advanced or Metastatic Sarcoma |
PHASE2 | COMPLETED |
| TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer |
PHASE2 | UNKNOWN |
| Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE) |
PHASE1/PHASE2 | NOT_YET_RECRUITING |
| An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer. |
PHASE1/PHASE2 | COMPLETED |
| Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma |
PHASE1/PHASE2 | RECRUITING |
| AZD1775 for Advanced Solid Tumors |
PHASE1 | COMPLETED |
| A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors |
PHASE1 | RECRUITING |
| Phase I Study for Safety and Efficacy of P276-00 in Subjects With Myeloma |
PHASE1 | WITHDRAWN |
| Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms |
PHASE1 | COMPLETED |
| the Efficacy and Safety of Dalpiciclib Combined With Third-generation EGFR-TKI in Patients With EGFR Mutation and Meningial Metastasis in Non-small Cell Lung Cancer Progressing Through Third-generation TKI and Platinum-containing Two-drug Chemotherapy |
nan | UNKNOWN |
| Co'Moon for Supporting Breast Cancer Patients on Adjuvant Endocrine Therapy |
nan | COMPLETED |
| Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer |
nan | COMPLETED |
Related proteins — ESM-2 sequence neighbours (a CCNT2 binder may also engage these)